The study tracked nearly 700 patients who underwent TAVI at one of two facilities in Melbourne, Australia, over a ten-year period. 

Researchers tracked the outcomes of more than 45,000 patients who participated in one of four randomized trials.

The authors tracked data from more than 22,000 PCI patients who participated in one of 10 randomized trials.

COVID-19 patients presenting with ST-segment elevation myocardial infarction (STEMI) experience a high rate of stent thrombosis.

Rapid reperfusion is linked to improved survival for STEMI patients, but delayed care is still prevalent. 

When patients have stable ischemic heart disease, two primary treatment options are revascularization followed by guideline-directed medical therapy (GDMT) or GDMT alone.

Such attributes as patient outcomes, efficiency and available resources were used to develop the list, which includes a tie at No. 10. 

Operators who performed at least 16 uLMS-PCIs per year were associated with improved survival.

The researchers explored data from orthotopic heart transplant patients who were hospitalized for COVID-19 at one of two facilities.

The device will be tested in high-risk percutaneous coronary intervention (PCI) patients.

Fractional flow reserve guidance can help cardiologists make better decisions during percutaneous coronary intervention—can it lead to better outcomes for patients with stable angina pectoris?

When patients with coronary in-stent restenosis (ISR) require reintervention, should specialists turn to drug-coated balloon (DCB) angioplasty or a drug-eluting stent (DES)?